I could see many post from @Peeteepoo and others about MPL could succeed to treat Alzheimer's Dementia, however I do not deny that's still a possibility but I disagree that at current stage PAA should not embark on that path and deviate from its primary target to treat MND as MPL has already shown a great deal confidence with efficacy an effectiveness (58% improvement). Once we have enough creditability with MPL, we can certainly also trial Alzheimers and Dementia. What the new board/management need to focus (IMO) are:I'll be keep watching how things unfolds in next few weeks, months and beyond. I still trust science and believe on success of MPL to treat unmet need of MND.
- First thing first, get all necessary members of BoD asap with experience and credibility. A Small but effective BoD add more value to shareholders (as I have seen with NEU and DXB). [A mixture of SME, finance background and also who have succeeded in getting FDA approval will add more credit, not sure if MT will be still interested. We already have a wold class technical advisory board of neurologist/SME, head of manufacturing and head of operations with medical background]
- Secure confidence of shareholder and new investors by releasing updated ALSFRS-R and Survival Analysis to be generated by Berry Consultants as you have promised to update this data in coming weeks (from last Investor presntation)
- The recent FDA ODD designation to MPL was wasted with selfish outgoing board, I suggest to take proactive approach to advertise superiority of of MPL over already available drugs (QALSODY and RILUTEK) with evidence of data.
- Provide shareholders a time line with clear targets and keep the promise intact as market do not like uncertainty. I understand there is a lot more things happening in the background with recent BoD reshuffle but give us a chance to trust you that you have made a paradigm shift to outgoing board.
The release of survival analysis from Barry consulting next week will change momentum in SP appreciation.
- Forums
- ASX - By Stock
- PAA
- PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-352
-
- There are more pages in this discussion • 627 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $50.92K | 290.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 152309 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 329859 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 152309 | 0.175 |
13 | 381650 | 0.170 |
7 | 256513 | 0.165 |
8 | 396304 | 0.160 |
6 | 336734 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 329859 | 3 |
0.185 | 267471 | 5 |
0.190 | 722743 | 7 |
0.195 | 575777 | 10 |
0.200 | 302726 | 11 |
Last trade - 15.48pm 11/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |